Baxter Expands Injectable Product Line

Baxter International Inc. has announced five new injectable pharmaceutical product launches in the U.S., bringing their total to 10 for 2024. The recent additions include Micafungin for Candida infections, Cyclophosphamide for malignant diseases, Pantoprazole Sodium for GERD and hypersecretion conditions, Cefazolin in a new strength for antibacterial use, and Levetiracetam for seizure therapy.

These ready-to-use formats aim to improve healthcare efficiency by simplifying preparation processes, reducing contamination risks, and enhancing patient safety. These products are now available in the U.S. for healthcare providers.